GW4064: Non-Steroidal FXR Agonist for Metabolic and Fibrosis Research

Executive Summary: GW4064 is a synthetic, non-steroidal agonist of the farnesoid X receptor (FXR), exhibiting high selectivity and potency (EC50 as low as 15 nM in receptor assays) [product info]. It activates FXR to regulate bile acid, cholesterol, and triglyceride metabolism, and has been shown to suppress TLR4 signaling and promote ferroptosis in fibrotic models [DOI]. APExBIO supplies GW4064 (SKU B1527) as a research tool for pathway dissection, not as a therapeutic drug, due to solubility and photoinstability constraints. This article reviews GW4064's mechanism, evidence base, experimental parameters, and critical misconceptions, integrating the latest peer-reviewed and workflow findings.

Biological Rationale

Farnesoid X receptor (FXR, NR1H4) is a nuclear receptor central to the regulation of bile acid synthesis, lipid, and cholesterol metabolism [internal]. FXR modulates hepatic and intestinal homeostasis, responding to endogenous bile acids and synthetic agonists. Disruption of FXR signaling is implicated in metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and fibrosis [DOI]. The identification of potent, selective FXR agonists like GW4064 has enabled researchers to experimentally dissect FXR's physiological role in both health and disease.

Mechanism of Action of GW4064

GW4064 is a synthetic, non-steroidal, and highly selective FXR agonist. It binds to the ligand-binding domain of FXR, inducing a conformational change that promotes coactivator recruitment and transcriptional activation of FXR target genes [product]. GW4064 demonstrates an EC50 of 15 nM in isolated receptor assays and 90 nM in human FXR-transfected cell models, indicating high potency [internal]. Upon FXR activation, downstream genes involved in bile acid synthesis (e.g., CYP7A1 suppression), cholesterol transport, and triglyceride regulation are modulated. Recent research also shows that GW4064 activation of FXR in hepatic stellate cells leads to TLR4 inhibition and enhancement of ferroptosis, thereby reducing collagen deposition and fibrotic response [DOI].

Evidence & Benchmarks

• GW4064 activates human FXR with an EC50 of 90 nM in transfected cell assays (product info).
• In isolated receptor assays, GW4064 demonstrates an EC50 of 15 nM, highlighting its high affinity and selectivity (internal).
• In metabolic disease models (KK-Ay and ob/ob mice), GW4064 lowers serum triglyceride and very low-density lipoprotein (VLDL) secretion, indicating efficacy in lipid regulation (internal).
• In hepatic stellate cell (LX-2) models exposed to nickel oxide nanoparticles, GW4064 activation of FXR suppresses TLR4 expression, increases ferroptosis markers, and reduces collagen deposition (DOI).
• GW4064 is insoluble in water and ethanol but is soluble in DMSO at concentrations ≥24.7 mg/mL, supporting its use in cell-based assays but limiting physiological applications (product info).

Applications, Limits & Misconceptions

GW4064 (SKU B1527) from APExBIO is primarily used as a research tool to interrogate FXR activation in metabolic, hepatic, and fibrotic models. Its ability to modulate cholesterol and triglyceride regulation, as well as bile acid metabolism pathways, makes it valuable for basic and translational studies [internal]. However, GW4064 is not suitable for therapeutic use due to its limited solubility, photoinstability (stilbene moiety), and potential toxicity under UV light. It remains a reference standard for in vitro and preclinical in vivo FXR signaling pathway analysis.

Common Pitfalls or Misconceptions

• GW4064 is not a drug candidate for human therapy due to poor solubility, instability, and toxicity (product info).
• It should not be stored in solution for extended periods; prompt use of freshly prepared DMSO solutions at -20°C is essential for stability (product info).
• GW4064's effects are specific to FXR and do not generalize to all nuclear receptors or metabolic pathways (internal).
• Photoinstability (stilbene core) can lead to rapid degradation under UV light—protect solutions and samples from light at all times (product info).
• Not all animal models respond identically; interpretation of metabolic or fibrotic phenotypes requires context-specific validation (DOI).

Workflow Integration & Parameters

When integrating GW4064 into metabolic or fibrosis research, consider the following protocol parameters and best practices:

Protocol Parameters

• Compound preparation: Dissolve GW4064 in DMSO at concentrations ≥24.7 mg/mL for stock solutions; avoid water or ethanol (product info).
• Storage: Store GW4064 as a solid at -20°C; prepare solutions immediately before use and protect from light.
• Cellular assays: Typical working concentrations in vitro range from 0.1 to 10 μM; titrate as needed for cell type and endpoint (DOI).
• Animal studies: Dosing regimens reported in mouse models vary but often employ daily dosing by intraperitoneal injection; consult primary literature for species- and endpoint-specific recommendations (internal).
• Control compounds: Use FXR antagonists or vehicle controls to validate specificity of FXR-mediated effects.
• Readouts: Assess FXR target gene expression (e.g., SHP, BSEP), TLR4 expression, and markers of ferroptosis (e.g., GPX4, GSH) where relevant.
• Photoprotection: Always handle solutions and experimental plates away from UV light to maintain compound integrity.

For stepwise bench guidance and troubleshooting, see this workflow article, which expands on application-specific nuances not fully covered here.

Conclusion & Outlook

GW4064 remains the reference non-steroidal FXR agonist for metabolic and fibrosis research, enabling granular interrogation of lipid homeostasis, bile acid metabolism, and FXR/TLR4/ferroptosis crosstalk in preclinical models. The latest evidence shows FXR agonism with GW4064 not only regulates canonical metabolic targets but also suppresses pro-fibrotic TLR4 signaling and promotes ferroptosis in hepatic stellate cells [DOI]. While its physicochemical limitations preclude therapeutic application, its precision and reliability support continued use as a research tool. This article extends prior reviews (see here for mechanistic focus) by providing up-to-date, protocol-driven guidance and clarifying boundaries of GW4064's utility.